3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Breast Neoplasms
20
Carcinoma, Renal Cell
10
Neuroendocrine Tumors
7
Neoplasm Metastasis
7
Recurrence
4
Tuberous Sclerosis
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Endometrial Neoplasms
3
von Hippel-Lindau Disease
2
Skin Neoplasms
2
Sarcoma
2
Meningioma
2
Glioma
2
Gastro-enteropancreatic neuroendocrine tumor
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Hepatocellular
2
Adenoma, Islet Cell
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
zimberelimab
1
pembrolizumab
1
olaparib
1
lutetium Lu 177 dotatate
1
lanreotide
1
fluorodopa F 18
1
cabozantinib
1
Sunitinib
1
Random Allocation
1
Octreotide
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
Everolimus
×
1 year
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled